LIXTE Receives US Patent Application Notification for Immuno-Oncology Page 1

Patent Covers combining LIXTE’s LB-100
with various innovative cancer immunotherapies

PASADENA, Calif., Sept. 4, 2024 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc.(Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 16/467,721, entitled “Oxabicycloheptanes for Modulation of Immune Response,” for combining the Company’s LB-100 compound with several innovative cancer immunotherapies.